Navigation Links
Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL

CORK, Ireland, March 29, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals announced today that four abstracts reporting research findings with TMC435, the company's investigational hepatitis C protease inhibitor, have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, March 30 to April 3, 2011.  

The four abstracts for TMC435 support Tibotec's continued efforts to advance its research and development program for the treatment of HCV.  TMC435 highlights at the meeting include one oral presentation and one late-breaker poster presentation:

  • Analysis of the predictive nature of IL28B genotype and pretreatment serum IP-10 in treatment-naive HCV patients from phase IIb PILLAR study on TMC435 administered with pegIFN/ribavirin
  • Results from interim 24 week data of the international phase IIb randomized, double-blind, placebo-controlled ASPIRE study on efficacy, tolerability, safety, and pharmacokinetics of TMC435 administered with pegIFN/ribavirin in treatment-experienced HCV patients

  • "Tibotec is committed to developing innovative new treatment options that may offer better treatment outcomes and that may decrease the duration of treatment for patients with chronic hepatitis C infection," said Brian Woodfall M.D., Vice President of Global Clinical Development at Tibotec. "The company's presence at this year's EASL meeting and the recent launch of the phase 3 clinical trial program for TMC435 reinforce the value of this investigational agent in our growing HCV pipeline."

    The titles of the abstracts and times for Tibotec's presentations on TMC435 appear below – full abstracts can also be accessed at

    Oral Presentation:

  • "Impact of IL28B genotype and pretreatment serum IP-10 in treatment-naive genotype-1 HCV patients treated with TMC435 in combination with peginterferon alpha-2a and ribavirin in PILLAR study" – Thursday, March 31, 2011 from 17:00 to 19:00

  • Poster Presentations:

  • Late-breaker "The ASPIRE trial: TMC435 in treatment-experienced patients with genotype-1 HCV infection who have failed previous PEG/RBV treatment" – Thursday, March 31, 2011 to Saturday, April 2, 2011
  • "Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment" – Thursday, March 31, 2011 from 09:00 to 18:00
  • "Treatment outcome and resistance analysis in HCV genotype-1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with pegIFNalpha-2a/ribavirin" – Saturday, April 2, 2011 from 09:00 to 18:00

  • About HCVHCV is a blood-borne infectious disease that affects the liver. With an estimated 170 million people infected worldwide and three to four million people newly infected each year, HCV puts a significant burden on patients and society. Chronic infection with HCV can lead to liver cancer and other serious and fatal liver diseases, and is the most common cause of liver transplant worldwide.  The current standard of care for HCV, pegylated interferon combined with ribavirin, causes serious side effects and only cures 40 to 50 percent of genotype 1 patients. The development of new therapies, particularly direct antivirals with different modes of action, may allow HCV patients to undergo a shorter and more effective treatment regimen.

    About Tibotec Pharmaceuticals Tibotec Pharmaceuticals is a global pharmaceutical and research development company and one of the companies that compose the Janssen Pharmaceutical Companies of Johnson & Johnson. The Company's main research and development facilities are in Beerse, Belgium with offices in Titusville, NJ and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need. Contacts: Media

    Investor RelationsKaren Manson: Cell + 32 (479) 89 47 99Stan Panasewicz: (732) 524-2524Louise Mehrotra: (732) 524-6491

    SOURCE Tibotec Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
    2. 3-D printing method advances electrically small antenna design
    3. SG Biofuels Advances Jatropha Biotech Platform with Application of Genetic Markers to Reference Genome
    4. Redpoint Advances Salt Enhancer Discovery Program
    5. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
    6. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
    7. New treatment for rabies advances after successful phase 1 trial in India
    8. Reportlinker Adds Advances in Biopharmaceutical Technology in China
    9. New Advances in Understanding of Parasite Risk Showcased at CVBD World Forum
    10. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
    11. Fulton Project Advances to Phase 2 of Loan Guarantee Process
    Post Your Comments:
    (Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
    (Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
    (Date:11/24/2015)... ... 24, 2015 , ... Creation Technologies would like to extend ... 2015 Technology Fast 500 list of the fastest growing companies in North America. ... medical device that speeds up orthodontic tooth movement by as much as 50 ...
    (Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
    Breaking Biology Technology:
    (Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
    (Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
    (Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
    Breaking Biology News(10 mins):